BackLexaria Bioscience - Warrants (11/01/2026) Overview

Lexaria Bioscience - Warrants (11/01/2026) Total Assets

Lexaria Bioscience - Warrants (11/01/2026)'s total assets is $4.8M.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$4.78M
29.07% YoYΔ $-1.96M vs prior year quarter

Peer trimmed avg / median

Loading

Lexaria Bioscience - Warrants (11/01/2026) Total Assets History

Loading

Lexaria Bioscience - Warrants (11/01/2026) vs. peers: Total Assets Comparison

Loading

Lexaria Bioscience - Warrants (11/01/2026) Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Lexaria Bioscience - Warrants (11/01/2026) (LEXXW) FAQ

As of the most recent data (May 2026), LEXXW shows a total assets of $4.8M. That compares with $6.7M in the prior-year period — down 29.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LEXXW's total assets is now $4.8M (was $6.7M) — a 29.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Lexaria Bioscience - Warrants (11/01/2026) is outperforming or lagging.

Tracking LEXXW's total assets over time shows whether Lexaria Bioscience - Warrants (11/01/2026) is scaling, shrinking, or reshaping that part of the business. The current reading is $4.8M That compares with $6.7M in the prior-year period — down 29.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total assets page, Stockcircle has Lexaria Bioscience - Warrants (11/01/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total assets (currently $4.8M) with ownership activity and broader fundamentals.

Lexaria Bioscience - Warrants (11/01/2026)'s total assets is $4.8M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.